(Q33584142)

28 July 2017

1 reference

title

Outcomes of pharmacological and surgical treatment for obesity (English)

1 reference

28 July 2017

0 references

Cerulli J

1

1 reference

PubMed ID

10186466

28 July 2017

Malone M

series ordinal

2

1 reference

28 July 2017

1 September 1998

1 reference

28 July 2017

1 reference

28 July 2017

14

1 reference

28 July 2017

3

1 reference

28 July 2017

269-283

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199814030-00004

28 July 2017

0 references

cites work

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

12 December 2020

Current views on obesity

1 reference

12 December 2020

Dexfenfluramine in type II diabetes: effect on weight and diabetes control.

1 reference

12 December 2020

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

1 reference

12 December 2020

Quality of life assessment of morbidly obese patients: effect of weight-reducing surgery

1 reference

12 December 2020

A one-year trial to assess the value of orlistat in the management of obesity

1 reference

12 December 2020

Medical hazards of obesity

1 reference

12 December 2020

Sibutramine--a review of clinical efficacy

1 reference

12 December 2020

1 reference

12 December 2020

Social and economic effects of body weight in the United States

1 reference

12 December 2020

Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine

1 reference

12 December 2020

Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.

1 reference

12 December 2020

The 25-year health care costs of women who remain overweight after 40 years of age

1 reference

12 December 2020

Actual causes of death in the United States

1 reference

12 December 2020

Use and abuse of appetite-suppressant drugs in the treatment of obesity

1 reference

12 December 2020

Costs and benefits when treating obesity

1 reference

12 December 2020

Lipase inhibition: a novel concept in the treatment of obesity

1 reference

12 December 2020

Obesity, health services use, and health care costs among members of a health maintenance organization.

1 reference

12 December 2020

The impact of obesity on health status: some implications for health care costs

1 reference

12 December 2020

Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes

1 reference

12 December 2020

Pathophysiology of obesity

1 reference

12 December 2020

Sibutramine: a review of the pharmacology of a novel anti-obesity agent

1 reference

12 December 2020

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity

1 reference

12 December 2020

Long-term weight control study: conclusions

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

1 reference

12 December 2020

Descriptive epidemiology of body weight and weight change in U.S. adults

1 reference

12 December 2020

Quality of life after gastroplasty is normal: a controlled study.

1 reference

12 December 2020

The cost of obesity: the US perspective

1 reference

12 December 2020

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

12 December 2020

Impairment of health and quality of life in people with large waist circumference.

1 reference

12 December 2020

Clinical studies with dexfenfluramine: from past to future

1 reference

12 December 2020

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity

1 reference

12 December 2020

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

1 reference

12 December 2020

Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase

1 reference

12 December 2020

Swedish obese subjects (SOS)--an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity

1 reference

12 December 2020

Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years

1 reference

12 December 2020

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

1 reference

12 December 2020

Perioperative risks and safety of surgery for severe obesity

1 reference

12 December 2020

Valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

International trial of long-term dexfenfluramine in obesity.

1 reference

12 December 2020

Comparison of the costs associated with medical and surgical treatment of obesity

1 reference

12 December 2020

The International Primary Pulmonary Hypertension Study (IPPHS)

1 reference

12 December 2020

Sibutramine in weight control: a dose-ranging, efficacy study

1 reference

12 December 2020

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

1 reference

12 December 2020

The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Body Weight and Mortality among Women

1 reference

12 December 2020

Long-term weight control study. VI. Individual participant response patterns

1 reference

12 December 2020

Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.

1 reference

12 December 2020

Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication

1 reference

12 December 2020

Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs ,

1 reference

12 December 2020

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

1 reference

12 December 2020

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study

1 reference

12 December 2020

1 reference

12 December 2020

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

12 December 2020

10.2165/00019053-199814030-00004

Identifiers

DOI

1 reference

PubMed ID

10186466

Dimensions Publication ID

28 July 2017

0 references

1 reference

PubMed ID

10186466